直肠腺癌保器官试验:放疗加量能否提高保器官率?
该研究为OPRA随机试验的事后分析,纳入303例II/III期直肠腺癌患者,比较标准剂量与高剂量放疗 boost 对临床完全缓解率和保器官率的影响。
要点
- 标准剂量组3年和5年保器官概率均为52%,高剂量组分别为47%和45%。
- 高剂量组T3/T4期患者比例更高(83% vs 62%),但保器官率无显著差异。
核心结论
- 在局部晚期直肠癌全程新辅助治疗中,较高的放疗 boost 剂量与临床完全缓解概率或保器官持久性无显著关联。
研究设计与样本
- OPRA试验为随机临床试验,本文为事后分析,纳入303例II/III期直肠腺癌患者,其中标准剂量 boost 组93例,高剂量 boost 组210例。
主要发现
- 标准剂量组3年和5年保器官概率均为52%(95%CI 43-64),高剂量组3年为47%(95%CI 41-54),5年为45%(95%CI 38-52)。
关键数值与推荐
- 放疗照射原发肿瘤及受累淋巴结剂量为4500 cGy,同步化疗。
- 标准 boost 剂量为500-540 cGy,可选高剂量 boost 为900-1100 cGy。
- 标准剂量组中位总剂量为5000 cGy,高剂量组中位总剂量为5400 cGy。
临床怎么用
- 对于希望保器官的直肠癌患者,不应仅以提高 boost 剂量来追求更高临床完全缓解率或保器官率。
局限性
- 本文为事后分析,非预设主要终点分析。
- 高剂量组T3/T4期患者比例显著更高,组间基线不平衡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The Organ Preservation in Patients with Rectal Adenocarcinoma trial was a randomized clinical trial investigating the optimal sequencing of total neoadjuvant therapy for patients with rectal cancer desiring organ preservation (OP). An optional higher-dose radiation boost was allowed on this trial. We aimed to determine whether a higher radiation boost dose was associated with the probability of clinical complete response and OP. METHODS AND MATERIALS: Patients with clinical stage II/III rectal adenocarcinoma were randomized to induction chemotherapy followed by chemoradiation or chemoradiation followed by consolidation chemotherapy. Radiation therapy was delivered to the primary tumor and involved nodes to 4500 cGy with concurrent chemotherapy. The standard boost dose to the primary tumor was 500 to 540 cGy, but the treating physician was allowed to give an optional higher-dose boost of 900 to 1100 cGy. Post-total neoadjuvant therapy restaging assessment with flexible sigmoidoscopy and magnetic resonance imaging stratified patients into 3 tiers of clinical response. Patients with a clinical complete or near-complete response were offered OP, whereas those with an incomplete clinical response were recommended for total mesorectal excision. In a post hoc analysis, OP rates by radiation boost dose (standard-dose [SD] vs high-dose [HD] boost) were estimated using the Kaplan-Meier method and tested for statistical significance using the log-rank test. Tumor clinical response rates were estimated using proportions and tested for statistical significance using the Fisher exact test. RESULTS: Of the 324 patients randomized in the Organ Preservation in Patients with Rectal Adenocarcinoma trial, 303 patients were eligible for the present analysis, including 93 patients in the SD boost group (median total dose, 5000 cGy) and 210 in the HD boost group (median total dose, 5400 cGy). Clinical T3/T4 stage at presentation was more common among HD patients (83% and 10%, respectively) compared with SD patients (62% and 18%, respectively) (P < .001); otherwise, the 2 groups were comparable in all other measured aspects. Rates of restaging endoscopic clinical complete response and near-complete response were similar among SD patients (41% and 44%, respectively) and HD patients (44% and 39%, respectively) (P = .5). The median follow-up for patients with OP was 5.14 (IQR, 3.75-5.67) years. The 3- and 5- year probability of OP were both 52% (95% CI, 43-64) for SD patients, and 47% (95% CI, 41-54) and 45% (95% CI, 38-52) for HD patients, respectively. CONCLUSIONS: In the prospective phase 2 Organ Preservation in Patients with Rectal Adenocarcinoma trial of total neoadjuvant therapy for locally advanced rectal cancer, a higher radiation boost dose was not significantly associated with the probability of achieving a clinical complete response or the durability of OP.
引用
- Yariv O, Williams H, Goodman KA, et al. Does Radiation Boost Dose Affect Organ Preservation Rates? A Secondary Analysis of the Organ Preservation in Patients With Rectal Adenocarcinoma Trial. Int J Radiat Oncol Biol Phys. 2026. PMID: 42142103. doi:10.1016/j.ijrobp.2026.03.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。